Elation Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 39)
Elation Health logo

Elation Health

EmergingHealthcare

Clinical EHR

San Francisco primary care EHR for independent and DPC practices with physician-first clinical workflow design; $50M+ backed competing with athenahealth for 35,000+ independent primary care providers.

AI VisibilityBeta
Overall Score
D39
Category Rank
#439 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
41
Gemini
36

About

Elation Health is a San Francisco-based electronic health record (EHR) platform built specifically for primary care physicians and independent practices — providing a physician-designed clinical workflow system for internal medicine, family medicine, and pediatrics practices that prioritize direct patient relationships over corporate health system integration requirements. Founded in 2010 by Kyna Fong and backed with $50+ million raised from Kinnevik, Sapphire Ventures, and others, Elation Health serves 35,000+ primary care providers across independent practices, direct primary care (DPC) clinics, concierge medicine, and federally qualified health centers.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

39
Overall Score
81
#439
Category Rank
#17
76
AI Consensus
71
stable
Trend
stable
40
ChatGPT
80
41
Perplexity
75
36
Gemini
77
44
Claude
86
34
Grok
85

Key Details

Category
Clinical EHR
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Elation Health
Clinical EHR

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.